METHOD FOR DETERMINING THE PROGNOSIS OF THE EFFECTIVENESS OF BREAST CANCER THERAPY Russian patent published in 2021 - IPC G01N33/48 G01N33/574 C12Q1/6886 A61B10/04 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to oncology, and is intended to predict the effectiveness of neoadjuvant chemotherapy for breast cancer. The patient's non-fixed tumor tissue is harvested using a core-biopsy method. Tumor-infiltrating lymphocytes (TIL) with a subpopulation of lymphocytes are quantified by flow cytometry with their verification by light microscopy with counting the number of lymphoid cells in 10 fields of view. Subpopulations of TIL CD45+/CD14- и CD3-CD19+. are determined. The level of expression of the intracellular marker Ki67 and the progesterone receptor (PR) is determined. The HER2 marker is determoned. At a concentration of CD45+/CD14- cells ≥ 4,3%, CD3-CD19+ cells ≤ 4%, Ki67 positive cells ≤ 50%, the absence of HER2 expression on tumor cells and a concentration of PR positive cells ≤10% the effectiveness of neoadjuvant chemotherapy is predicted.

EFFECT: invention provides for the determination of the prognosis of the efficacy of the neoadjuvant therapy option intended to be administered in a particular patient on the basis of the qualitative and quantitative characteristics of TIL and their subpopulation.

1 cl, 2 dwg, 1 tbl, 1 ex